Mpm. Stokkel et al., PRETREATMENT SERUM LACTATE-DEHYDROGENASE AS ADDITIONAL STAGING PARAMETER IN PATIENTS WITH SMALL-CELL LUNG-CARCINOMA, Journal of cancer research and clinical oncology, 124(3-4), 1998, pp. 215-219
At present the standard staging procedure in patients with small-cell
lung cancer (SCLC) is extensive, expensive and time-consuming. Further
more, the predictive and prognostic value of the current staging syste
m is poor. To determine the value of pretreatment clinical and biochem
ical parameters to predict tumour stage and to assess prognosis, a ret
rospective study was performed of 121 consecutive patients with newly
diagnosed SCLC. Methods: On the basis of routine diagnostic procedures
, 51 patients were staged as having limited disease and 70 patients as
having extensive disease. During follow-up, data on tumour progressio
n and survival were gathered. These data and the tumour stage were cor
related with lactate dehydrogenase (LDH), alkaline phosphatase, liver
enzymes, leucocyte count, protein, albumin, calcium, age and gender. R
esults: Follow-up ranged from 1 week to 96 months, during which 110 pa
tients died. In all patients with LDH levels above 400 U/l n = 31), me
tastases were found at the initial stage, whereas all patients initial
ly staged as having limited disease and LDH levels above 240 U/l showe
d tumour progression. Bone and liver were found to be the most commonl
y involved sites, whereas the incidence of brain metastases increased
during followup. In patients initially staged as having limited diseas
e, no differences in survival were found between those showing local r
ecurrence and those developing metastases during follow-up (P = 0.67),
Compared to the patients initially staged as having extensive disease
, the survival of both groups was significantly better (P < 0.001). Si
gnificant independent variables of survival were LDH, albumin, initial
stage and gender, but LDH was the best overall predictor (P < 0.001).
Conclusion: These results suggest that pretreatment LDH may be used a
s an additional staging parameter in SCLC, which can identify prognost
ic subgroups before treatment.